Research programme: herpes simplex virus type 2 vaccines - Genocea Biosciences

Drug Profile

Research programme: herpes simplex virus type 2 vaccines - Genocea Biosciences

Alternative Names: GEN-002; HSV-2 prophylactic (Px) vaccine - Genocea Biosciences; HSV-2 Px; ICP4383-766 + gD2; ICP4383-766 + TMR341-363; ICP4383-766 and gD2

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fred Hutchinson Cancer Research Center; Genocea Biosciences; University of Washington
  • Developer Genocea Biosciences
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Herpes simplex virus type 2 infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections(Prevention) in USA (Parenteral)
  • 06 May 2015 Genocea plans to file an IND application for Herpes simplex virus infections (Genocea Biosciences 10-K, May 2015)
  • 05 Dec 2013 Preclinical development of a prophylactic HSV-2 vaccine is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top